Logo

KYMR

Kymera Therapeutics, Inc.

KYMR

Kymera Therapeutics, Inc. • NASDAQ
$67.88 ▲ 0.03% (+0.02)
Market Cap $4.88 B
52w High $68.80
52w Low $19.45
Dividend Yield 0%
P/E -18.86
Volume 325.99K
Outstanding Shares 71.95M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $2.764M ▼ $21.191M ▼ $-82.175M ▼ -2.973K% ▼ $-0.94 ▲ $-79.326M ▼
Q2-2025 $11.476M ▼ $93.949M ▼ $-76.614M ▼ -667.602% ▼ $-0.95 ▼ $-74.422M ▼
Q1-2025 $22.1M ▲ $96.526M ▲ $-65.581M ▲ -296.747% ▲ $-0.82 ▲ $-63.461M ▲
Q4-2024 $7.394M ▲ $88.149M ▲ $-70.752M ▼ -956.884% ▲ $-0.88 ▼ $-68.706M ▼
Q3-2024 $3.741M $75.865M $-62.487M -1.67K% $-0.82 $-60.44M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $505.682M ▼ $1.102B ▼ $155.786M ▼ $946.258M ▼
Q2-2025 $665.445M ▲ $1.131B ▲ $159.588M ▲ $971.48M ▲
Q1-2025 $463.15M ▼ $918.312M ▼ $132.079M ▼ $786.233M ▼
Q4-2024 $488.744M ▼ $978.035M ▼ $142.416M ▲ $835.619M ▼
Q3-2024 $549.97M $1.035B $141.912M $892.93M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-82.175M ▼ $-27.11M ▲ $-235.299M ▼ $39.51M ▼ $-222.899M ▼ $-27.291M ▲
Q2-2025 $-76.614M ▼ $-59.884M ▲ $60.021M ▲ $245.726M ▲ $245.863M ▲ $-60.579M ▲
Q1-2025 $-65.581M ▲ $-79.15M ▼ $48.615M ▼ $258K ▼ $-30.277M ▼ $-79.617M ▼
Q4-2024 $-70.752M ▼ $-61.784M ▼ $68.568M ▲ $2.765M ▼ $9.549M ▼ $-62.72M ▼
Q3-2024 $-62.487M $-50.19M $-157.68M $250.918M $43.048M $-50.001M

Five-Year Company Overview

Income Statement

Income Statement Kymera is still very much a research-stage company. Its revenue is small and irregular, coming mainly from partnerships rather than product sales. The core story on the income statement is steady, sizable operating losses driven by high research and development spending and growing overall costs as the pipeline advances. Losses per share have deepened over time, especially in the most recent year, which is typical for a biotech scaling up clinical activity but means there is no sign of economic profitability yet.

Balance Sheet

Balance Sheet The balance sheet looks like that of a well-capitalized, early-stage biotech. Total assets and shareholder equity have risen meaningfully over the past few years, reflecting capital raises and partnership funding. Cash has improved compared with the early years but remains a finite resource relative to the rate of spending, so the company is still dependent on careful cash management. Debt is present but modest, and the business appears primarily equity-funded, which reduces financial leverage risk but also means continued dilution is a possibility if more capital is needed.

Cash Flow

Cash Flow Cash flow shows a clear pattern: money steadily flows out to fund R&D and operations, with no offsetting product inflows yet. Operating cash flow has been negative in most years and has become more negative as programs move forward, indicating rising cash burn. Capital spending on equipment and facilities is small, so free cash flow closely tracks operating cash flow and is also negative. This profile is normal for a platform biotech but underscores the importance of future funding events, milestone payments, or eventual commercial success to sustain the business over time.

Competitive Edge

Competitive Edge Kymera occupies a differentiated niche in biotechnology by focusing on targeted protein degradation, especially in immunology. Its Pegasus platform and detailed mapping of E3 ligases provide a technical foundation that is not easy to replicate, and partnerships with large pharma players validate the approach and extend its reach. At the same time, the broader protein degradation field is attracting more competitors, and Kymera remains reliant on a limited number of key programs and collaborators. Until it has approved products, its competitive position rests mainly on scientific leadership, intellectual property, and the strength of its collaborations rather than on market share.

Innovation and R&D

Innovation and R&D Innovation is Kymera’s main asset. The company is pushing a cutting-edge modality with multiple first-in-class or best-in-class oral degraders in immunology and early work in oncology. The Pegasus platform and E3 ligase atlas give it a systematic way to find and design new drugs, and the pipeline spans partnered and wholly owned programs, which balances risk and potential reward. Heavy R&D spending is driving current losses but is also building a broad portfolio, with several important clinical readouts expected over the next couple of years that will test whether the scientific promise turns into real therapeutic value.

Summary

Kymera is an early, science-driven biotech: low and uneven collaboration revenue, substantial and growing operating losses, but a strengthened balance sheet supported mainly by equity and partnerships. Cash burn is significant and rising, which is typical for a company at this stage but implies ongoing dependence on external funding or successful milestones. Competitively, Kymera stands out in targeted protein degradation for immunology, reinforced by proprietary technology and big-pharma alliances, yet faces the usual clinical, regulatory, and financing uncertainties of pre-commercial biotech. The investment case hinges less on current financial performance and more on whether its innovative platform and pipeline can eventually translate into approved medicines and a sustainable business model.

NEWS

November 25, 2025 · 7:00 AM UTC

Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Read more

November 24, 2025 · 7:00 AM UTC

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

Read more

November 3, 2025 · 7:00 AM UTC

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

Read more

October 28, 2025 · 7:00 AM UTC

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025

Read more

October 27, 2025 · 7:00 AM UTC

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting

Read more